Table 5.
Recent clinical trials with coated liposomes.
| Drug | Formulation/Coating Technology | Used for | Expected Results after the Clinical Trial | Phase | Clinicaltrials.gov Identifier |
|---|---|---|---|---|---|
| Bupivacaine | Liposomal bupivacaine/DepoFoam technology | Opioid use pain, postoperative colectomy colorectal surgery |
A substantially longer duration of action than normal bupivacaine (96 h versus 8–9 h, respectively) | IV | NCT03638635 |
| 2B3-101- (glutathione (GSH) pegylated liposomal doxorubicin hydrochloride formulation) | PEG coating | Meningeal carcinomatosis | Coating liposomes with PEG guarantees that they circulate for a longer period of time in plasma | II | NCT01818713 |
| Anti-EGFR immunoliposomes loaded with doxorubicin | Attached are monoclonal antibodies or antibody fragments to the surface of liposomes (immunoliposomes, antibody-linked nanoparticles) | Solid tumors | Immunoliposomes coated with antibodies bind more selectively to antigens expressed on target cells, and they are internalized more efficiently. Drug resistance can be overcome by such delivery systems | I | NCT01702129 |
| Liposomal astaxanthin | Not specified | Bioavailability of astaxanthin formulations | Human crossover pharmacokinetic study pathways of astaxanthin in the bloodstream | Not applicable | NCT02397811 |
| Doxil | Not specified | Breast cancer | Assess the effectiveness of using heat therapy in addition to the chemotherapy drug Doxil to treat recurrent breast cancer that has spread to the chest wall after mastectomy | II | NCT02192021 |